Sensus Healthcare Announces Preliminary Q4 Revenue Of $12M And 2023 Revenue Exceeding $23M
Portfolio Pulse from Benzinga Newsdesk
Sensus Healthcare, Inc. (NASDAQ:SRTS) has announced preliminary Q4 revenue of over $12M and expects 2023 revenue to exceed $23M. The company shipped more than 60 SRT units in 2023 and will report full financial results on February 8th. The increase in revenue is attributed to the growing use of superficial radiotherapy for non-melanoma skin cancer, favorable reimbursement, an aging population, and clinical results. Sensus anticipates further interest from prospective customers at upcoming trade shows in Q1 2024.
January 23, 2024 | 1:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sensus Healthcare expects Q4 revenue over $12M and 2023 revenue exceeding $23M, with more than 60 SRT units shipped. Anticipates increased interest at upcoming trade shows.
The positive preliminary revenue announcement for Q4 and the full year of 2023 is likely to be viewed favorably by investors, potentially leading to a short-term increase in stock price. The anticipation of heightened interest from trade shows could further bolster investor confidence.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100